Ductal carcinoma in situ (DCIS) now represents 20–25% of all 'breast cancers' consequent
upon detection by population-based breast cancer screening programmes. Currently, all …

Ductal carcinoma in situ (DCIS) refers to breast epithelial cells that have become
“cancerous” but still reside in their normal place in the ducts and lobules. In this setting …

Background The current debate on overdiagnosis and overtreatment of screen-detected
ductal carcinoma in situ (DCIS) urges the need for prospective studies to address this issue …

The transition from ductal carcinoma in situ to invasive ductal carcinoma is a key event in
breast cancer progression that is still not well understood. To discover the microRNAs …

With the widespread adoption of population-based breast cancer screening, ductal
carcinoma in situ (DCIS) has come to represent 20–25% of all breast neoplastic lesions …

Background The ductal carcinoma in situ (DCIS) of the mammary gland represents an early,
pre-invasive stage in the development of invasive breast carcinoma. Since DCIS is a curable …

Molecular mechanisms mediating the progression of ductal carcinoma in situ (DCIS) to
invasive breast cancer remain largely unknown. We used gene expression profiling of …

Sentinel lymph node biopsy has become a standard staging tool in the surgical
management of breast cancer. The positive impact of sentinel lymph node biopsy on …

Invasive breast cancer represents the endpoint of a developmental process that originates in
the terminal duct lobular units and is believed to progress through stages of increasing …

In a substantial number of patients, ductal carcinoma in situ (DCIS) of the breast will never
progress to invasive ductal carcinoma, and these patients are often overtreated under the …